Menu
The steady growth of the pet population, both in the United States and globally, reflects the strong emotional bonds between humans and their dogs and cats. Our pets provide us with companionship, security and loyalty. We provide those qualities in return, but humans also provide the care needed by our pets to stay healthy and, when sick, to become healthy once again. As with humans, cancer is a serious and all too frequently fatal array of diseases that afflicts dogs and cats at the same rate as humans.
Most drugs to treat metastatic veterinary cancers were originally developed for human use and are now both generic and inexpensive. However, the effectiveness of these drugs against metastatic cancers is limited by the development of drug resistance and by potentially life-threatening adverse effects. New drugs that address these limitations in the treatment of human cancers are very often either ineffective for non-human patients or too expensive for pet owners to afford.
Our current drug development program builds on the initial success of our Chief Scientific Officer and Co-Founder, Dr. Mervyn Israel, whose innovative drug design and development efforts resulted in Valstar® (valrubicin) as a treatment for human bladder cancer. Paradox Pharmaceuticals has expanded this drug development strategy through basic and translational research of its founding partners at the University of Tennessee Health Science Center and the University of Mississippi, and through collaborative efforts with investigators at colleges of veterinary medicine at the University of Tennessee, Ohio State University, University of Missouri and Colorado State University.
The current Paradox Pharmaceuticals product pipeline includes the antitumor and cardioprotective compounds, benzarubicin and pivarubicin, the radiation enhancing agents, valrubicin and AD 36, and the non-cardiotoxic mixed-function antitumor drug, daunomustine.
Daunomustine is our lead veterinary chemotherapeutic agent, based on its pharmacological properties and advanced stage of clinical development. In addition to our advanced pipeline numerous related compounds are currently being investigated for both oncologic and non-oncologic therapeutic potential.
The research culminating in the development of the Paradox drug pipeline has been supported by the National Institutes of Health, the American Cancer Society, American Heart Association, Susan G. Komen for The Cure, The Pharmaceutical Manufacturers Association Foundation, The Morris Animal Foundation and other private investment in the cumulative amount of over $10 million.